Technologies
Immunotherapy
Mesenchymal Stem Cells (MSC) can be manipulated to
facilitate organ repair and regeneration and manipulate the individual’s immune
system. Their ability to accomplish both of these tasks is dependent on their
state of activation. The UIC inventors have discovered a new method to activate
these stem cells and transform them so that they can provide more effective
regeneration as well as more effective control of damaging immune system
processes.
Understanding complex immunological processes at the molecular level will give investigators and cli
In 2010, the market for anti-inflammatory
therapeutics is projected to exceed $40 billion at an average annual growth
rate of just over 10%. The market for
anti-inflammatory therapeutics for Rheumatoid Arthritis alone exceeds $12
billion per year. Scientists at the
university of Illinois at Chicago have discovered a novel therapeutic target
for treatment of these conditions.
According to the American Cancer Society, prostate cancer is the second leading cause of cancer death among men in the US. It is estimated that more than 200 thousand new cases are diagnosed every year and more than 30 thousand will die of this disease.
ALL OF THESE, ALL OF THESE, Urbana-Champaign, Cell Biology, Gene expression, regulation and signal transduction, Anti-inflammatory, Marker, Molecular Biology, Drug Design, Drug targets, Proteins, Immunotherapy, Drug delivery, Genomics/proteomics, Sythesis and Analysis, Research Tools and Reagants, Therapeutic
This technology marries the Recombinant Human Tissue Factor (TF) with Membrane Scaffold Protein (MSP) NanodiscsTM, resulting in an efficient and easy to administer blood c
In cancer, the signaling cascade for programmed cell death, apoptosis, is often mutated leading to resistance from natural pro-death signals. PAC-1 and related compounds are small molecules capable of specifically killing cancer cells by inducing apoptosis. It does so by targeting an inactive apoptotic precursor, procaspase-3, that is up regulated in many cancer types. In vitro and in vivo studies have shown PAC-1 to be efficacious in reducing tumor cells at doses that show no toxicity in normal counterparts.
Although there are already a few existing compounds for use in the treatment of bone diseases, these new compounds may have efficacy exceeding that of current commercial species.